The science or not behind deferrals of blood donors with a history of cancer.

BACKGROUND: In the United States (US), each blood center's medical director sets policy for donors with a cancer history. STUDY DESIGN AND METHODS: A subgroup of America's Blood Centers' (ABC) Scientific, Medical, and Technical Committee developed a survey to measure the determination of eligibility, policies for deferral and/or lookback when a donor reports a current diagnosis or history of cancer. A 31-question survey was sent to 47 ABC blood centers in North America via email. Survey results were compiled and literature evaluating the risk of cancer transmission by transfusion was reviewed. RESULTS: Responses were received from 37 centers (79%). Donors with a history of carcinoma or sarcoma who had completed treatment were accepted at 73% of centers with no further deferral. Donors with a history of leukemia or lymphoma were permanently deferred at 76% of centers. Donors with a myelodysplastic or myeloproliferative syndrome were deferred permanently at 86% of centers. Handling of donors with high white cell counts varied. Donors with cancer not in active treatment (i.e., prostate cancer) were subject to various deferrals. Center response to post-donation reports of cancer vary widely. Literature review yielded no evidence of transfusion-transmitted cancer. CONCLUSION: Cancer deferral policies vary widely among blood centers, and are not generally based on evidence, but on some aspect of the precautionary principle. As the donor population ages and so becomes more at risk of cancer, this approach may further reduce the available donor pool.

Detection of Babesia RNA and DNA in whole blood samples from US blood donations.

BACKGROUND: Human babesiosis is a zoonotic infection caused by an intraerythrocytic parasite. The highest incidence of babesiosis is in the United States, although cases have been reported in other parts of the world. Due to concerns of transfusion-transmitted babesiosis, the US Food and Drug Administration (FDA) recommended year-round regional testing for Babesia by nucleic acid testing or use of an FDA-approved device for pathogen reduction. A new molecular test, cobas Babesia (Roche Molecular Systems, Inc.), was evaluated for the detection of the four species that cause human disease, Babesia microti, Babesia duncani, Babesia divergens, and Babesia venatorum. STUDY DESIGN AND METHODS: Analytical performance was evaluated followed by clinical studies on whole blood samples from US blood donations collected in a special tube containing a chaotropic reagent that lyses the red cells and preserves nucleic acid. Sensitivity and specificity of the test in individual samples (individual donation testing [IDT]) and in pools of six donations were determined. RESULTS: Based on analytical studies, the claimed limit of detection of cobas Babesia for B. microti is 6.1 infected red blood cells (iRBC)/mL (95% confidence interval [CI]: 5.0, 7.9); B. duncani was 50.2 iRBC/mL (95% CI: 44.2, 58.8); B. divergens was 26.1 (95% CI: 22.3, 31.8); and B. venatorum was 40.0 iRBC/mL (95% CI: 34.1, 48.7). The clinical specificity for IDT was 99.999% (95% CI: 99.996, 100) and 100% (95% CI: 99.987, 100) for pools of six donations. CONCLUSION: cobas Babesia enables donor screening for Babesia species with high sensitivity and specificity.

Two cases of transfusion-transmitted Anaplasma phagocytophilum.

Anaplasma phagocytophilum, the causative agent of human granulocytic anaplasmosis, is an obligate intracellular bacterium most commonly acquired from tick bites. High seroprevalence rates in endemic regions suggest that transfusion transmission of A phagocytophilum would be a common event; however, only 2 cases have previously been reported. The exact cause of this discrepancy is not known. Whole blood leukocyte-reduction methods used by many blood centers are thought to reduce the risk of transfusion transmission of many pathogens, including A phagocytophilum. We report 2 additional cases of transfusion-transmitted A phagocytophilum in which leukocyte reduction of all transfused units failed to prevent microbial transmission.

Ciliated hepatic foregut cyst in a patient with renal cell carcinoma.

BACKGROUND: Ciliated hepatic foregut cyst is a rare condition almost always found incidentally on a computerized tomography scan or at autopsy. Rarely, portal vein compression can be a presenting finding. The cysts are usually unilocular and occur with greater frequency in males. There is a predilection for the left lobe. The cysts average 3 cm in size. CASE PRESENTATION: We present in this case report a ciliated hepatic foregut cyst found incidentally in the setting of renal carcinoma. The patient was a man known to have a large renal mass, assumed to be cancer, and a liver mass suspicious for metastatic disease. This liver mass was cystic and upon further analysis showed ciliated epithelial lining. We describe the gross and histological appearance, as well as a brief discussion of ciliated hepatic foregut cysts. CONCLUSION: We report the first case of a patient with coexisting renal cell carcinoma and a ciliated hepatic foregut cyst. While this may represent a coincidental finding, a possibility of a neoplastic or non-neoplastic disorder associated with ciliated hepatic foregut cysts can not be completely ruled out.